SG11201903770UA - Combination treatments comprising imidazopyrazinones for the treatment of psychiatric and/or cognitive disorders - Google Patents

Combination treatments comprising imidazopyrazinones for the treatment of psychiatric and/or cognitive disorders

Info

Publication number
SG11201903770UA
SG11201903770UA SG11201903770UA SG11201903770UA SG11201903770UA SG 11201903770U A SG11201903770U A SG 11201903770UA SG 11201903770U A SG11201903770U A SG 11201903770UA SG 11201903770U A SG11201903770U A SG 11201903770UA SG 11201903770U A SG11201903770U A SG 11201903770UA
Authority
SG
Singapore
Prior art keywords
valby
lundbeck
international
ottiliavej
cognitive disorders
Prior art date
Application number
SG11201903770UA
Inventor
Jan Kehler
Lars Rasmussen
Morten Langgård
Mikkel Jessing
Paulo Vital
Karsten Juhl
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of SG11201903770UA publication Critical patent/SG11201903770UA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property MD 1101111 0 DOI HIM 011101 0 01111H111101111111111111111111111111111111111 Organization International Bureau (10) International Publication Number (43) International Publication Date .....0\"\" WO 2018/078038 Al 03 May 2018 (03.05.2018) W I P0 I P C T (51) International Patent Classification: MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, A61K 31/4985 (2006.01) A61P 25/18 (2006.01) TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, A61K 31/5377 (2006.01) A61P 25/22 (2006.01) KM, ML, MR, NE, SN, TD, TG). A61K 31/55 (2006.01) A61P 25/24 (2006.01) A61K 45/06 (2006.01) A61P 25/28 (2006.01) Published: (21) International Application Number: — with international search report (Art. 21(3)) PCT/EP2017/077497 (22) International Filing Date: 26 October 2017 (26.10.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: PA201600659 28 October 2016 (28.10.2016) DK (71) Applicant: H. LUNDBECK A/S [DK/DK]; Ottiliavej 9, 2500 Valby (DK). (72) Inventors: KEHLER, Jan; c/o H. Lundbeck A/S Ottili- avej 9, 2500 Valby (DK). RASMUSSEN, Lars, Kyhn; c/ o H. Lundbeck A/S Ottiliavej 9, 2500 Valby (DK). LANG- GARD, Morten; c/o H. Lundbeck A/S Ottiliavej 9, 2500 Valby (DK). JESSING, Mikkel; c/o H. Lundbeck A/S Ot- tiliavej 9, 2500 Valby (DK). VITAL, Paulo, Jorge, Vieira; c/o H. Lundbeck A/S Ottiliavej 9, 2500 Valby (DK). JUHL, Karsten; c/o H. Lundbeck A/S Ottiliavej 9, 2500 Valby (DK). Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (81) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, (84) 1-1 ot (54) Title: COMBINATION TREATMENTS COMPRISING IMIDAZOPYRAZINONES FOR THE TREATMENT OF PSYCHIA- en TRIC AND/OR COGNITIVE DISORDERS 0 GP (57) : The present invention provides combination treatments comprising administration of compounds that are PDE1 enzyme 1 r - - inhibitors and other compounds useful in the treatment of psychiatric and/or cognitive disorders such as for example Attention Deficit 0 ---. Hyperactivity Disorder (ADHD), depression, anxiety, narcolepsy, schizophrenia, cognitive impairment or cognitive impairment asso- ciated with schizophrenia (CIAS). Separate aspects of the invention are directed to the combined use of said compounds for the treat- 1-1 © ment of psychiatric and/or cognitive disorders. The present invention also provides pharmaceutical compositions comprising said PDE1 N enzyme inhibitors together with other compounds useful in the treatment of psychiatric and/or cognitive disorders. C
SG11201903770UA 2016-10-28 2017-10-26 Combination treatments comprising imidazopyrazinones for the treatment of psychiatric and/or cognitive disorders SG11201903770UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA201600659 2016-10-28
PCT/EP2017/077497 WO2018078038A1 (en) 2016-10-28 2017-10-26 Combination treatments comprising imidazopyrazinones for the treatment of psychiatric and/or cognitive disorders

Publications (1)

Publication Number Publication Date
SG11201903770UA true SG11201903770UA (en) 2019-05-30

Family

ID=60186299

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201903770UA SG11201903770UA (en) 2016-10-28 2017-10-26 Combination treatments comprising imidazopyrazinones for the treatment of psychiatric and/or cognitive disorders

Country Status (29)

Country Link
US (1) US10905688B2 (en)
EP (1) EP3532064B1 (en)
JP (1) JP2019536762A (en)
KR (1) KR20190075068A (en)
CN (1) CN109803658A (en)
AR (1) AR109991A1 (en)
AU (1) AU2017350473A1 (en)
BR (1) BR112018013247A2 (en)
CA (1) CA3041607A1 (en)
CL (1) CL2019001091A1 (en)
CO (1) CO2019002909A2 (en)
CY (1) CY1123396T1 (en)
DK (1) DK3532064T3 (en)
ES (1) ES2816005T3 (en)
HR (1) HRP20201326T1 (en)
HU (1) HUE050403T2 (en)
IL (1) IL265635A (en)
LT (1) LT3532064T (en)
MA (1) MA46611B1 (en)
ME (1) ME03821B (en)
MX (1) MX2019004763A (en)
PL (1) PL3532064T3 (en)
PT (1) PT3532064T (en)
RS (1) RS60716B1 (en)
RU (1) RU2019109039A (en)
SG (1) SG11201903770UA (en)
SI (1) SI3532064T1 (en)
WO (1) WO2018078038A1 (en)
ZA (1) ZA201902091B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201629064A (en) 2014-10-10 2016-08-16 Ｈ 朗德貝克公司 Triazolopyrainones as PDE1 inhibitors
JO3627B1 (en) 2015-04-30 2020-08-27 H Lundbeck As Imidazopyrazinones as PDE1 inhibitors
TWI729109B (en) 2016-04-12 2021-06-01 丹麥商Ｈ 朗德貝克公司 1,5-DIHYDRO-4H-PYRAZOLO[3,4-d]PYRIMIDIN-4-ONES AND 1,5-DIHYDRO-4H-PYRAZOLO[4,3-c]PYRIDIN-4-ONES AS PDE1 INHIBITORS
CN109843884B (en) 2016-10-18 2022-03-04 H.隆德贝克有限公司 Imidazopyrazinones, pyrazolopyrimidinones and pyrazolopyridinones as PDE1 inhibitors
US10912773B2 (en) 2016-10-28 2021-02-09 H. Lundbeck A/S Combinations comprising substituted imidazo[1,5-a]pyrazinones as PDE1 inhibitors
AU2017350473A1 (en) 2016-10-28 2019-04-18 H. Lundbeck A/S Combination treatments comprising imidazopyrazinones for the treatment of psychiatric and/or cognitive disorders
TWI803570B (en) 2018-02-01 2023-06-01 日商日本香煙產業股份有限公司 Nitrogen-containing heterocyclic amide compound and its medical application

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB973361A (en) 1960-05-11 1964-10-28 Ciba Ltd Pyrazolo-pyrimidines and process for their manufacture
DE19709877A1 (en) 1997-03-11 1998-09-17 Bayer Ag 1,5-dihydro-pyrazolo [3,4-d] pyrimidinone derivatives
MY144532A (en) 2001-08-20 2011-09-30 Lundbeck & Co As H Novel method for down-regulation of amyloid
DE10238723A1 (en) 2002-08-23 2004-03-11 Bayer Ag Phenyl substituted pyrazolyprimidines
DE10238724A1 (en) 2002-08-23 2004-03-04 Bayer Ag New 6-alkyl-1,5-dihydro-4H-pyrazolo-(3,4-d)-pyrimidin-4-ones useful as selective phosphodiesterase 9A inhibitors for improving attention, concentration, learning and/or memory performance
DE10238722A1 (en) 2002-08-23 2004-03-11 Bayer Ag Improving attention, concentration, cognition, learning and/or memory performance, using selective phosphodiesterase 9A inhibitors, preferably 4H-pyrazolo-(3,4-d)-pyrimidin-4-one derivatives
WO2004099211A1 (en) 2003-05-09 2004-11-18 Bayer Healthcare Ag 6-cyclylmethyl- and 6-alkylmethyl-substituted pyrazolopyrimidines
EP1828192B1 (en) 2004-12-21 2014-12-03 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
EP1919287A4 (en) 2005-08-23 2010-04-28 Intra Cellular Therapies Inc Organic compounds for treating reduced dopamine receptor signalling activity
US8012936B2 (en) 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
JP5837278B2 (en) 2006-12-05 2015-12-24 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． New use
MX2009011830A (en) 2007-05-11 2009-11-13 Pfizer Amino-heterocyclic compounds.
CA2706986A1 (en) 2007-11-30 2009-06-04 Elbion Gmbh Aryl and heteroaryl fused imidazo (1,5-a) pyrazines as inhibitors of phosphodiesterase 10
UA105362C2 (en) 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
KR20110063447A (en) 2008-09-08 2011-06-10 베링거 인겔하임 인터내셔날 게엠베하 Pyrazolopyrimidines and their use for the treatment of cns disorders
CA2740396A1 (en) 2008-12-06 2010-06-10 Intra-Cellular Therapies, Inc. Organic compounds
TWI404721B (en) 2009-01-26 2013-08-11 Pfizer Amino-heterocyclic compounds
EP2440234A4 (en) 2009-06-10 2013-11-06 Univ New York Immunological targeting of pathological tau proteins
WO2011153136A1 (en) 2010-05-31 2011-12-08 Intra-Cellular Therapies, Inc. Organic compounds
RS59652B1 (en) 2010-08-12 2020-01-31 Lilly Co Eli Anti-n3pglu amyloid beta peptide antibodies and uses thereof
PL2619208T3 (en) 2010-09-20 2017-03-31 Ironwood Pharmaceuticals, Inc. Imidazotriazinone compounds
US20130196986A1 (en) 2010-09-21 2013-08-01 Marc Labroli Triazolopyrazinones as p2x7 receptor antagonists
JO3089B1 (en) 2010-11-19 2017-03-15 H Lundbeck As Imidazole derivatives as PDE10A enzyme inhibitors
AR085840A1 (en) * 2011-04-05 2013-10-30 Otsuka Pharma Co Ltd MEDICINAL PRODUCT CONTAINING A COMPOUND THAT IS 7- [4- (4-BENZO [B] TIOFEN-4-IL-PIPERAZIN-1-IL) BUTOXI] -1H-QUINOLIN-2-ONA
WO2012136552A1 (en) 2011-04-08 2012-10-11 H. Lundbeck A/S ANTIBODIES SPECIFIC TO PYROGLUTAMATED Αβ
US10561656B2 (en) 2011-06-10 2020-02-18 Intra-Cellular Therapies, Inc. Organic compounds
US9643970B2 (en) 2011-10-10 2017-05-09 H. Lundbeck A/S Substituted imidazo [1,5-a]pyrazines as PDE9 inhibitors
EP2807163B1 (en) 2012-01-26 2017-03-22 H. Lundbeck A/S Pde9 inhibitors with imidazo triazinone backbone
BR112014031730B1 (en) 2012-06-18 2023-05-16 Dart Neuroscience (Cayman) Ltd PHARMACEUTICALLY ACCEPTABLE COMPOUNDS OR SALTS THEREOF AND THEIR USE
EP2970279B1 (en) 2013-03-15 2020-09-16 Intra-Cellular Therapies, Inc. Organic compounds
JP5783297B2 (en) 2013-08-06 2015-09-24 株式会社デンソー Mechanical quantity sensor
TW201609700A (en) 2014-02-19 2016-03-16 Ｈ 朗德貝克公司 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahydropyridines as BACE1 inhibitors for treatment of alzheimer's disease
JP5797815B1 (en) 2014-06-27 2015-10-21 細田建設株式会社 Post-installed anchor and its construction method
CA2961186A1 (en) 2014-09-18 2016-03-24 Sunovion Pharmaceuticals Inc. Tricyclic derivative
US20160083400A1 (en) 2014-09-18 2016-03-24 Sunovion Pharmaceuticals Inc. Tricyclic guanidine derivative
US20160083391A1 (en) 2014-09-18 2016-03-24 Sunovion Pharmaceuticals Inc. Tricyclic piperazine derivative
TW201629064A (en) * 2014-10-10 2016-08-16 Ｈ 朗德貝克公司 Triazolopyrainones as PDE1 inhibitors
CR20170187A (en) 2014-11-10 2018-02-01 H Lundbeck As 2-Amino-3,5-difluoro-6-methyl-6-phenyl-3,4,5,6-tetrahydropyridines as BACE1 inhibitors for the treatment of Alzheimer's disease
JO3458B1 (en) 2014-11-10 2020-07-05 H Lundbeck As 2-Amino-6-(difluoromethyl)- 5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as BACE1 inhibitors
MA40941A (en) 2014-11-10 2017-09-19 H Lundbeck As 2-AMINO-5,5-DIFLUORO-6- (FLUOROMETHYL) -6-PHENYL-3,4,5,6-TETRAHYDROPYRIDINES AS BACE1 INHIBITORS
TW201639851A (en) 2015-03-16 2016-11-16 大日本住友製藥股份有限公司 Bicyclic imidazolo derivative
US20160311831A1 (en) 2015-04-22 2016-10-27 H. Lundbeck A/S Imidazotriazinones as PDE1 Inhibitors
JO3627B1 (en) 2015-04-30 2020-08-27 H Lundbeck As Imidazopyrazinones as PDE1 inhibitors
JO3711B1 (en) 2015-07-13 2021-01-31 H Lundbeck As Antibodies specific for hyperphosphorylated tau and methods of use thereof
PE20181015A1 (en) 2015-08-12 2018-06-26 H Lundbeck As 2-AMINO-3-FLUORO-3- (FLUOROMETHYL) -6-METI-6-PHENYL-3,4,5,6-TETRAHYDROPYRIDINES AS BACE1 INHIBITORS
CN105254635A (en) * 2015-10-30 2016-01-20 中国药科大学 Imidazo pyrazine compound, medicine composition of imidazo pyrazine compound and purpose of imidazo pyrazine compound
AR107456A1 (en) 2016-02-12 2018-05-02 Lilly Co Eli PDE1 INHIBITOR
TWI729109B (en) 2016-04-12 2021-06-01 丹麥商Ｈ 朗德貝克公司 1,5-DIHYDRO-4H-PYRAZOLO[3,4-d]PYRIMIDIN-4-ONES AND 1,5-DIHYDRO-4H-PYRAZOLO[4,3-c]PYRIDIN-4-ONES AS PDE1 INHIBITORS
JP2018076285A (en) 2016-09-14 2018-05-17 大日本住友製薬株式会社 Pharmaceuticals containing bicyclic imidazolo derivatives
CN109843884B (en) 2016-10-18 2022-03-04 H.隆德贝克有限公司 Imidazopyrazinones, pyrazolopyrimidinones and pyrazolopyridinones as PDE1 inhibitors
US10912773B2 (en) 2016-10-28 2021-02-09 H. Lundbeck A/S Combinations comprising substituted imidazo[1,5-a]pyrazinones as PDE1 inhibitors
AU2017350473A1 (en) 2016-10-28 2019-04-18 H. Lundbeck A/S Combination treatments comprising imidazopyrazinones for the treatment of psychiatric and/or cognitive disorders

Also Published As

Publication number Publication date
CY1123396T1 (en) 2021-12-31
PL3532064T3 (en) 2020-11-16
BR112018013247A2 (en) 2018-12-04
CL2019001091A1 (en) 2019-07-05
CA3041607A1 (en) 2018-05-03
SI3532064T1 (en) 2020-10-30
AU2017350473A1 (en) 2019-04-18
MX2019004763A (en) 2019-07-01
WO2018078038A1 (en) 2018-05-03
AR109991A1 (en) 2019-02-13
CN109803658A (en) 2019-05-24
ES2816005T3 (en) 2021-03-31
US20190282571A1 (en) 2019-09-19
ZA201902091B (en) 2020-10-28
HRP20201326T1 (en) 2020-11-27
RU2019109039A (en) 2020-11-30
MA46611A (en) 2019-09-04
KR20190075068A (en) 2019-06-28
ME03821B (en) 2021-04-20
IL265635A (en) 2019-05-30
EP3532064A1 (en) 2019-09-04
RU2019109039A3 (en) 2021-01-29
RS60716B1 (en) 2020-09-30
DK3532064T3 (en) 2020-08-24
LT3532064T (en) 2020-09-25
CO2019002909A2 (en) 2019-06-19
PT3532064T (en) 2020-09-03
EP3532064B1 (en) 2020-07-29
JP2019536762A (en) 2019-12-19
US10905688B2 (en) 2021-02-02
MA46611B1 (en) 2020-08-31
HUE050403T2 (en) 2020-12-28

Similar Documents

Publication Publication Date Title
SG11201903770UA (en) Combination treatments comprising imidazopyrazinones for the treatment of psychiatric and/or cognitive disorders
SG11201903061YA (en) Combination treatments comprising administration of imidazopyrazinones
SG11201810117WA (en) Human platelet lysate derived extracellular vesicles for use in medicine
SG11201805044WA (en) Compounds useful as kinase inhibitors
SG11201811432WA (en) Rna for cancer therapy
SG11201808990QA (en) Compositions for topical application of compounds
SG11201900163PA (en) Macrocycle kinase inhibitors
SG11201810628XA (en) Nasal pharmaceutical compositions with a porous excipient
SG11201903483VA (en) Compositions and methods for treating ezh2-mediated cancer
SG11201810420YA (en) Antibodies to alpha-synuclein and uses thereof
SG11201808221QA (en) 1,5-dihydro-4h-pyrazolo[3,4-d]pyrimidin-4-ones and 1,5-dihydro-4h-pyrazolo[4,3-c]pyridin-4-ones as pde1 inhibitors
SG11201810965YA (en) 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors
SG11201810280YA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201807913XA (en) Stabilized soluble pre-fusion rsv f proteins
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201408318RA (en) Compositions and methods for transmucosal absorption
SG11201900349VA (en) Somatostatin modulators and uses thereof
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201901494UA (en) Acid-alpha glucosidase variants and uses thereof
SG11201807827VA (en) Process for the preparation of pegylated drug-linkers and intermediates thereof
SG11201903892UA (en) [1,2,4]triazolo[1,5-a]pyrimidine derivatives as pde2 inhibitors
SG11201900443VA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201900551WA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201900546UA (en) Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
SG11201805001UA (en) Method of treating influenza a